Journal Overview

The Journal of Advanced Immunopharmacology, published by Brieflands, is a peer-reviewed journal dedicated to advancing the understanding of immunopharmacology, immunology, and the pharmacological modulation of immune responses. The journal serves as a platform for sharing groundbreaking research and insights in these fields, with a focus on bridging the gap between basic immunology and clinical pharmacology. It encourages interdisciplinary collaboration to promote the development of innovative therapeutic strategies. The journal welcomes original research articles, reviews, clinical case studies, clinical trials, and commentaries, covering topics such as immunopharmacology, immunological mechanisms, pharmacological interventions, translational research, therapeutic strategies, drug development, and public health.

Journal of Advanced Immunopharmacology
Frequency :quarterly

Verified by Ministry of Health and Medical Education, more
Abstracted/Indexed: WHO-EMRO Index Medicus, more
Scope: Immunology,  Pharmacology and Pharmacological modulation of Immune response, more
Copyright Policy: CC BY-NC 4.0
Publishing Access: Open Access
Peer Review Policy: Double-Blind Peer Review System Open Peer Review

Recent Articles

3 articles
2024-11-30
vol.4,issue4

Explore the latest articles published in this journal for impactful research and the newest advancements in the field.

30
Nov
2024
J Adv Immunopharmacol
Research Article

Analysis of Hotspot PIK3CA Mutations (E542K and E545K) in Iranian Colorectal Cancer Patients

Mohammad Amin BehmaneshORCID,
Zahra Masouri,
Mohammad Reza Abyaz,
Habib Habibimoghadam,
Abbas MoridniaORCID*

|

Final Published

30
Nov
2024
J Adv Immunopharmacol
Editorial

Targeting Platelets and NK Cells to Improve Radiation Therapy Outcomes

Abdolkarim SheikhiORCID*,
Rupak Pathak,
Myron R. Szewczuk

|

Final Published

30
Nov
2024
J Adv Immunopharmacol
Research Article

Investigating the Effect of Vitamin D Administration on the Severity of Neuropathic Pain in Diabetic Patients of Dezful City in 2025

Malihe MoeinjozanORCID,
Hamid KarimiORCID*,
Marjan AliabdiORCID,
Mansoureh BabadiORCID

|

Final Published

Journal Metrics

Discover our most recent insights and updates.

Submit to First Decision (Days) :
57
Accept to Publication (Days) :
15
Acceptance Rate (%)
29
Article Processing Charges :
Free

Keywords

Share it!

Author Services

Brieflands Author Services

Contact Us!